GC Biopharma Receives Marketing Authorization for Varicella Vaccine 'BARYCELA Inj.' in Guatemala
- First regulatory clearance in Latin America marks a strategic milestone for regional market expansion - World's first antibiotic-free manufacturing process ensures superior safety profile YONGIN, South Korea, March 26, 2026 /PRNewswire/ -- GC...
GC Biopharma Publishes a Comprehensive Review Paper Summarizing 30 Years of Accumulated Data on Its Proprietary Varicella Vaccine Strain, 'MAV/06'
Demonstrates effectiveness comparable to the global standard Oka strain vaccine YONGIN, South Korea, March 11, 2026 /PRNewswire/ -- GC Biopharma(006280.KS), a leading provider of biopharmaceutical products in South Korea, announced today that a...
GC Biopharma's Varicella Vaccine Strain 'MAV/06' Listed in WHO Position Paper
Officially recognized by WHO as a standard varicella vaccine strain alongside Oka Interchangeability endorsed, enhancing global supply security YONGIN, South Korea, Dec. 2, 2025 /PRNewswire/ -- GC Biopharma (006280.KS), a global biopharmaceutical...